The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
Extended Adjuvant Neratinib Improves DFS in Phase III Breast Cancer Study
Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly extended improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab
T-DM1 Poised to Set New Standard in HER2-Positive Metastatic Breast Cancer
The antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) will have an impact on the entire spectrum of care for patients with metastatic HER2-positive breast cancer, resulting in a greater emphasis on patient selection protocols and testing.
Trastuzumab-Associated Cardiac Events Reversible, Outweighed by Benefits
July 14th 2014Cardiac events associated with trastuzumab are mostly reversible and outweighed by significant extensions in OS and PFS for patients with HER2-positive breast cancer, according to analyses from several clinical trials exploring the drug.
Charles M. Perou, PhD, Discusses Genomic Signatures and Dual HER2-Targeting in Breast Cancer
June 13th 2014Charles M. Perou, PhD, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting that analyzed gene expression signatures in patients with HER2-positive breast cancer treated with weekly paclitaxel and trastuzumab with or without lapatinib.
Negative ALTTO Results Reverberate for Lapatinib, Novel Clinical Trials
June 1st 2014A dual HER2-blockade strategy that added lapatinib to trastuzumab for the adjuvant treatment of women with early breast cancer failed to demonstrate a significant improvement in DFS over the standard therapy with trastuzumab alone.
New Options for Low-Risk, HER2-Positive Tumors Featured in Research Overview
May 7th 2014Fresh insights into outcomes for patients with low-risk, HER2-positive breast cancer suggest that adjuvant chemotherapy regimens with or without trastuzumab (Herceptin) should be considered as options for managing this growing population
Breast Cancer Expert Offers Views on Promising Strategies
Now that targeted therapies are available for the treatment of various subtypes of breast cancer, and many novel agents are under investigation, it is important for the oncology community to follow the latest advancements to give patients the best available options.
Blackwell Explores Emerging Trends in Treating HER2 Metastatic Breast Cancer
Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.